Cure My Disease

Don't miss your cure!

 Log in / Sign up

Donor t cells aim to fight severe COVID-19

NCT ID NCT07709637

Ongoing Disease control Sponsor: LucasBio Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This early-stage trial tests a therapy made from donor immune cells, called LB-DTK-COV19, in adults with severe COVID-19. The cells are designed to target the virus and are given as a single infusion. The study aims to find a safe dose and see if the treatment can improve symptoms and reduce viral levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
allogeneic SARS-CoV-2-specific T cells (LB-DTK-COV19)
What this could lead to
If successful, this approach could offer a new treatment option for severe COVID-19 by boosting the immune system's ability to fight the virus.
What could go wrong
This is a very early, small Phase 1 trial with only one participant, so results may not be generalizable. Safety and effectiveness are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 hematopoietic and lymphoid system neoplasm Infections pneumonia Signs and Symptoms, Respiratory viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 COVID-19 (SARS-COV-2 INFECTION)

Contacts and locations

Locations

  • The Catholic University of Korea Seoul St.Mary's Hospital

    Seoul, 06591, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.